TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomised Study Using Cinacalcet to Improve Achievement of Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With ESRD
Brief Summary: The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.


Options:
A: Arm Label: Cinacalcet; Type: EXPERIMENTAL; Interventions: Drug: Cinacalcet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
C: Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: Other: Standard of care | Arm Label: Cinacalcet; Type: OTHER; Interventions: Drug: cinacalcet | Intervention Type: DRUG; Name: cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care
D: Arm Label: IV Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with IV paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Arm Label: Oral paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with oral paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): IV Paricalcitol, Oral paricalcitol | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet (at sites with IV paricalcitol), Cinacalcet (at sites with oral paricalcitol)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Intra-Articular metHuIL-1ra (Anakinra) in Subjects With Osteoarthritis (OA) of the Knee
Brief Summary: The purpose of this study is to evaluate the clinical response in subjects with symptomatic OA of the knee following a single 50 mg anakinra, 150 mg anakinra or placebo intra-articular (IA) injection.


Options:
A: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
B: Arm Label: Anakinra; Type: EXPERIMENTAL; Interventions: Drug: Intra-articular metHuIL-1ra (anakinra) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Intra-articular metHuIL-1ra (anakinra); Assigned to Arm(s): Anakinra | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Brief Summary: The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.


Options:
A: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W
B: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Darbepoetin alfa - Group A; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo- Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa - Group A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo- Group B
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Brief Summary: This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.


Options:
A: Intervention Type: DRUG; Name: Sutent; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Arm 1
C: Arm Label: SU011248 (sunitinib); Type: EXPERIMENTAL; Interventions: Drug: SU011248 (sunitinib) | Intervention Type: DRUG; Name: SU011248 (sunitinib); Assigned to Arm(s): SU011248 (sunitinib)
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya
Brief Summary: The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SP, amodiaquine, piperaquine, dihdroartemisinin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: intermittent preventive treatment | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Du-Cotecxin | Intervention Type: DRUG; Name: SP, amodiaquine, piperaquine, dihdroartemisinin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intermittent preventive treatment; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Du-Cotecxin; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine with artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amodiaquine with artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: FeFum porridge + IPT of malaria; Type: EXPERIMENTAL; Interventions: Drug: SP/Amodiaquine + FeFum fortified porridge | Arm Label: IPT of malaria; Type: EXPERIMENTAL; Interventions: Drug: SP/amodiaquine | Arm Label: FeFum porridge; Type: EXPERIMENTAL; Interventions: Dietary Supplement: FeFum fortified porridge | Arm Label: FePP porridge; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferric pyrophosphate fortified porridge | Intervention Type: DRUG; Name: SP/amodiaquine; Assigned to Arm(s): IPT of malaria | Intervention Type: DIETARY_SUPPLEMENT; Name: FeFum fortified porridge; Assigned to Arm(s): FeFum porridge | Intervention Type: DRUG; Name: SP/Amodiaquine + FeFum fortified porridge; Assigned to Arm(s): FeFum porridge + IPT of malaria | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferric pyrophosphate fortified porridge; Assigned to Arm(s): FePP porridge | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya
Brief Summary: The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Seasonal IPT in children - Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Seasonal IPT in children - Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine with artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amodiaquine with artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sulphadoxine-pyrimethamine; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine, Drug: Sulphadoxine-pryrimethamine | Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: mefloquine, Drug: IPTi mefloquine | Arm Label: Chlorproguanil dapsone; Type: EXPERIMENTAL; Interventions: Drug: Chlorproguanil-dapsone, Drug: Chlorproguanil dapsone | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil-dapsone; Assigned to Arm(s): Chlorproguanil dapsone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sulphadoxine-pryrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: IPTi mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil dapsone; Assigned to Arm(s): Chlorproguanil dapsone
D: Arm Label: IPTp-DP; Type: EXPERIMENTAL; Interventions: Drug: IPTp-DP | Arm Label: ISTp-DP; Type: EXPERIMENTAL; Interventions: Drug: ISTp-DP | Arm Label: IPTp-SP; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPTp-SP | Intervention Type: DRUG; Name: IPTp-SP; Assigned to Arm(s): IPTp-SP | Intervention Type: DRUG; Name: IPTp-DP; Assigned to Arm(s): IPTp-DP | Intervention Type: DRUG; Name: ISTp-DP; Assigned to Arm(s): ISTp-DP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya
Brief Summary: The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Seasonal IPT in children - Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Seasonal IPT in children - Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine with artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amodiaquine with artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sulphadoxine-pyrimethamine; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine, Drug: Sulphadoxine-pryrimethamine | Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: mefloquine, Drug: IPTi mefloquine | Arm Label: Chlorproguanil dapsone; Type: EXPERIMENTAL; Interventions: Drug: Chlorproguanil-dapsone, Drug: Chlorproguanil dapsone | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil-dapsone; Assigned to Arm(s): Chlorproguanil dapsone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sulphadoxine-pryrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: IPTi mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil dapsone; Assigned to Arm(s): Chlorproguanil dapsone
D: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.
Brief Summary: The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.


Options:
A: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 003
C: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone Palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Paliperidone Palmitate; Assigned to Arm(s): 001

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma
Brief Summary: The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.


Options:
A: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan/Prednisone/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Prednisone/Velcade | Intervention Type: DRUG; Name: Melphalan/Prednisone/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Prednisone/Velcade; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
D: Arm Label: Part 1: VMP+Siltuximab 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab 8.3 mg/kg or 11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm B: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Intervention Type: DRUG; Name: Siltuximab11 mg/kg; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Siltuximab 8.3 mg/kg or 11 mg/kg; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm B: VMP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma
Brief Summary: The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.


Options:
A: Arm Label: Arm A: VMPT; Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Melphalan, Prednisone, Thalidomide | Arm Label: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bortezomib, Melphalan, Prednisone | Intervention Type: DRUG; Name: Bortezomib, Melphalan, Prednisone, Thalidomide; Assigned to Arm(s): Arm A: VMPT | Intervention Type: DRUG; Name: Bortezomib, Melphalan, Prednisone; Assigned to Arm(s): VMP
B: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
D: Arm Label: carfilzomib (A0); Type: EXPERIMENTAL; Interventions: Drug: carfilzomib | Arm Label: carfilzomib (A1); Type: EXPERIMENTAL; Interventions: Drug: carfilzomib | Intervention Type: DRUG; Name: carfilzomib; Assigned to Arm(s): carfilzomib (A0) | Intervention Type: DRUG; Name: carfilzomib; Assigned to Arm(s): carfilzomib (A1)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents
Brief Summary: Due to progressive therapy intensification in the four consecutive studies AML-BFM 78, 83, 93 and 98, prognosis for children with acute myeloid leukemia (AML) has improved steadily. In spite of the intensified therapy, rates of morbidity and mortality have remained unchanged or have even decreased. Against the background that about 40% of the patients still die from immediate causes of an underlying disease relapse or of nonresponse, it seems to be justifiable to intensify therapy - especially for high-risk patients - which on its parts will require an optimization of supportive measures. As the present risk stratification into standard- (SR) and high-risk (HR) patients has proved effective, we will pursue the risk-adapted therapy strategy.

The aim of the study is to improve prognosis in children with AML by intensification of cytostatic therapy and to evaluate by randomisation the equivalence of a prophylactic central nervous system (CNS) irradiation with a total dose of 18 Gy versus 12 Gy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: liposomal daunorubicin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anthracyclines | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: 2-CDA | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: AI | Intervention Type: DRUG; Name: Anthracyclines; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: liposomal daunorubicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 2-CDA; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AI; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Daunorubicine; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Two post-remission strategies; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Idarubicin versus daunorubicin; Assigned to Arm(s): N/A
D: Arm Label: Cytarabine low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Arm Label: Cytarabine intermediate dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Cytarabine intermediate dose, Cytarabine low dose

Answer: A